The Association of G2677T Polymorphism in MDR1 Gene with
Neutropenia Incidence in Breast Cancer Patients Treated by
Doxorubicin based Chemotherapy
Siti Syarifah
1*
, Dita Hasni
2
Tri Widyawati
1
and Dwi Rita Anggraini
3
1
Department of Pharmacology and Therapeutic, Faculty of Medicine, Universitas Sumatera Utara,
Medan, 20155, Indonesia
2
Department of Pharmmacology, Faculty of Medicine, Universitas Baiturrahmah, Padang, Indonesia
3
Department of Anatomy, Faculty of Medicine, Universitas Sumatera Utara, Medan, 20155, Indonesia
Keywords: Breast Cancer, Doxorubicin, MDR1, Polymorphism.
Abstract: MDR1 gene is a gene that encoded P-glycoprotein (P-gp), an active efflux pump for a variety of carcinogens
and cytostatics. It has been suggested that MDR1 polymorphisms G2677T contribute to the variability of
therapeutic outcome and side effects. The present study was conducted to investigate the relation of G2677T
polymorphisms in MDR1 gene with neutropenia incidence in breast cancer patients treated with doxorubicin
based chemotherapy. As many as 147 Indonesian women’ isolated DNA samples were amplified using the
PCR method. The analysis process of G2677T polymorphism were done by using PCR-RFLP method. The
frequencies of MDR1 G2677T genotype for homozygous GG, heterozygous GT and variant TT was 50
(34.01%), 78 (53.1%), and 19(12.9%) respectively. No association were found between MDR1 G2677T
polymorphisms with degree of neutropenia (p > 0.05). However, there was no significant deviation of allele
and genotype frequency from Hardy-Weinberg Equilibrium
1 INTRODUCTION
Breast cancer is the second most frequent cancer
experienced by women in both well developed and
developing countries with the number of newly
diagnosed cases being 1.7 million women in the
world.(World Cancer Research, 2015). The
administration of chemotherapy as one of the
important things in the management of breast cancer
patients increased life expectancy but also various
side effects (Vulsteke et al, 2013). One of the most
dangerous side effects of chemotherapy is bone
marrow suppression that can be measured through
absolute neutrophil count (ANC). The condition of
neutropenia may cause patients at risk for infection
and result in delayed chemotherapy (Fung et al,
2014).
Current studies have showed, the development of
medical technologies such as gene sequencing, DNA
analysis and popularization of the idea of
"personalized medicine" have contributed significant
advances on how genetic patterns can be used to
predict the efficacy and safety of chemotherapy in
breast cancer (Milojkovic et al, 2011). The presence
of genetic polymorphisms in the MDR1 G2677T
(rs2032582) gene in exon 21 which encoded P-
glycoprotein (P-gp) associated with the increased of
neutropenia incidence due to chemotherapy. P-gp is a
transporter protein that acts as an active effluent
pump for various toxins including carcinogens and
medicines such as antineoplastic drugs like
doxorubicin and taxan. Interestingly, P-gp is mainly
expressed in bone marrow and peripheral leukocytes,
the presence of P-gp in bone marrow and peripheral
leukocytes certainly has a protective effect of cells
against drug accumulation into cells (Taheri et al,
2010). Several studies showed the relation of MDR1
polymorphism with hematological toxicities, but the
results was inconsistent and there was no many data
about MDR1 polymorphism in Indonesia (Cascorbi et
al, 2011).
Therefore, we evaluated the relationship of G2677
polymorphism with degree of neutropenia both
individually breast cancer patients who treated by
doxorubicin based chemotherapy. The results of this
study are expected to provide information related to
428
Syarifah, S., Hasni, D., Widyawati, T. and Anggraini, D.
The Association of G2677T Polymorphism in MDR1 Gene with Neutropenia Incidence in Breast Cancer Patients Treated by Doxorubicin based Chemotherapy.
DOI: 10.5220/0010044204280431
In Proceedings of the 3rd International Conference of Computer, Environment, Agriculture, Social Science, Health Science, Engineering and Technology (ICEST 2018), pages 428-431
ISBN: 978-989-758-496-1
Copyright
c
2021 by SCITEPRESS – Science and Technology Publications, Lda. All rights reserved